Compare DAL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAL | INSM |
|---|---|---|
| Founded | 1924 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2B | 33.5B |
| IPO Year | N/A | 2000 |
| Metric | DAL | INSM |
|---|---|---|
| Price | $70.03 | $156.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 24 |
| Target Price | $79.06 | ★ $192.27 |
| AVG Volume (30 Days) | ★ 8.3M | 2.7M |
| Earning Date | 01-13-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ 43.72 | N/A |
| EPS | ★ 7.66 | N/A |
| Revenue | ★ $63,364,000,000.00 | $447,022,000.00 |
| Revenue This Year | N/A | $53.83 |
| Revenue Next Year | $5.64 | $138.44 |
| P/E Ratio | $9.02 | ★ N/A |
| Revenue Growth | 2.79 | ★ 30.34 |
| 52 Week Low | $34.74 | $60.40 |
| 52 Week High | $73.16 | $212.75 |
| Indicator | DAL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 39.65 |
| Support Level | $64.47 | $150.80 |
| Resistance Level | $68.30 | $165.47 |
| Average True Range (ATR) | 2.15 | 6.33 |
| MACD | -0.12 | 0.26 |
| Stochastic Oscillator | 81.12 | 40.48 |
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.